🇺🇸 FDA

Intelligence Platform

Patents

Browse 259 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11246930

Reoviruses having modified sequences

ONCOLYTICS BIOTECH INC. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11242380

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Takeda Pharmaceutical Company Limited · Granted Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11229702

High concentration formulations of adalimumab

Coherus BioSciences, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11208405

Pyrrole derivatives as PLK1 inhibitors

SENTINEL ONCOLOGY LIMITED · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207351

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11207314

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202825

Attenuated infectious bronchitis virus

The Pirbright Institute · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11202802

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11191783

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11166985

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135247

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124839

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117934

Oncolytic virus platform to treat cancers with myxoma virus

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11103552

High concentration VEGF receptor fusion protein containing formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11077241

Standardizations and medical devices for the preparation of platelet rich plasma (PRP) or

RegenLab USA LLC · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11071755

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11065285

Biomarkers and combination therapies using oncolytic virus and immunomodulation

The Board of Regents of the University of Texas System · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11020436

Multipotent and immunocompatible stem cell concentrate

REGENERA—MEDICINA VETERINÁRIA AVANÇADA LTDA. · Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013767

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980793

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10973817

Pharmaceutical compounds

SENTINEL ONCOLOGY LIMITED · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953187

Configurable oxygen concentrator and related method

SEPARATION DESIGN GROUP LLC · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10946080

Compositions and methods for combination therapy with dengue virus and dendritic cells

PrimeVax Immuno-Oncology · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881689

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted